Wells Fargo & Company Calliditas Therapeutics Ab Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Calliditas Therapeutics Ab stock. As of the latest transaction made, Wells Fargo & Company holds 1,500 shares of CALT stock, worth $60,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,500
Previous 3,760
60.11%
Holding current value
$60,000
Previous $78,000
25.64%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CALT
# of Institutions
23Shares Held
843KCall Options Held
8.5KPut Options Held
26.6K-
Bvf Inc San Francisco, CA750KShares$30 Million0.89% of portfolio
-
Ironwood Investment Management LLC Boston, MA25.6KShares$1.03 Million0.56% of portfolio
-
Optiver Holding B.V. Amsterdam, P722.3KShares$893,4400.02% of portfolio
-
Crossmark Global Holdings, Inc.16.1KShares$644,6800.01% of portfolio
-
Ubs Group Ag10.8KShares$430,2400.0% of portfolio
About Calliditas Therapeutics AB
- Ticker CALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,624,800
- Market Cap $1.06B
- Description
- Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...